Peptide Dosage Chart (All Major Compounds): Studied Doses, Units, Frequency, Reconstitution

Key takeaways

Every dose on this page is a studied dose or a label dose, listed with its route, frequency, population and duration. None is a recommendation, and the pharmacy label on a prescribed product always overrides the chart.
Only a handful of compounds have a human dose at all. The GLP-1 drugs, tesamorelin and bremelanotide have FDA labels; sermorelin has small adult trials. BPC-157, TB-500, KPV, MOTS-c and injectable GHK-Cu have no studied human dose, and the charts sold with them were written by sellers.
The gap between studied doses and practice runs both ways: clinics prescribe sermorelin at a third to a seventh of the doses that moved IGF-1, while glutathione clinics infuse at or above the dose that failed its one randomized trial.
Units measure volume, not peptide. Units on an insulin syringe equal the dose in mg divided by the concentration in mg per mL, times 100. The same 10 units is 0.25 mg from one semaglutide vial and 0.5 mg from another, which is how the 5- to 20-fold overdoses FDA documented in 2024 happened.
As of October 2026 a US pharmacy may compound sermorelin, bremelanotide, glutathione, NAD+ and topical GHK-Cu, and the GLP-1 drugs only for a documented individual need. Tesamorelin is dispensed only as the brand Egrifta, because as a biological product it cannot be compounded. Everything else in the chart is sold as a research vial, with no label to follow.

How to read this chart

Each row answers five questions. What was studied gives the dose, route, frequency, population and duration of the key human study, or says plainly that none exists; the source label links to the study at the bottom of the page. Label dose is the FDA prescribing information where an approved product exists; most rows say none. What clinics or sellers typically use is practice or seller claims, taken from the hubs, never a recommendation. May a US pharmacy compound it? comes from our legal tracker; a committee recommendation is not a permit, and nothing has been added to the permitted list as of October 9, 2026. Hub links the full profile.

Doses are written the way the study wrote them (mg, mcg, or mg per kilogram); where a dose is per kilogram, the 70 kg equivalent in parentheses is a conversion, not a dose. The arithmetic for turning any of them into syringe units is in the reconstitution and units section below.

GLP-1 drugs

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
Semaglutide	2.4 mg subcutaneously once weekly after a 16-week step-up from 0.25 mg; 1,961 adults with obesity and no diabetes, 68 weeks: weight change -14.9% versus -2.4% on placebo (Wilding 2021)	Wegovy: 0.25 mg weekly for 4 weeks, then 0.5, 1 and 1.7 mg at 4-week steps; usual maintenance 2.4 mg weekly, with higher maintenance doses for selected indications since 2026. Ozempic: up to 2 mg weekly for type 2 diabetes (Wegovy label)	Compounded vials of 2.5 or 5 mg per mL dosed in syringe units on the label schedule; 'microdosing' below 0.25 mg, which has no weight-loss data	Approved drug. Compounded only for a patient with a documented need the approved product cannot meet; the shortage ended February 21, 2025	Compounded semaglutide; dosage chart
Tirzepatide	5, 10 or 15 mg subcutaneously once weekly after a 20-week escalation; 2,539 adults with obesity and no diabetes, 72 weeks: -15.0%, -19.5% and -20.9% versus -3.1% (Jastreboff 2022)	Zepbound: 2.5 mg weekly for 4 weeks (a starting dose), then 5 mg; increases of 2.5 mg after at least 4 weeks each; maintenance 5, 10 or 15 mg; maximum 15 mg (Zepbound label)	Compounded multi-dose vials, commonly 5 to 20 mg per mL, dosed in units on the label schedule; 'microdosing' below 2.5 mg, which rests on one small phase 2 data point at 1 mg	Approved drug. Same rule as semaglutide; the shortage ended December 19, 2024	Compounded tirzepatide; dosage chart
Retatrutide	4, 9 or 12 mg subcutaneously once weekly; 2,339 adults with obesity and no diabetes, 80 weeks: -17.6%, -23.7% and -25.0% versus -3.9% by intention to treat; the phase 2 trial escalated from 2 mg (Jastreboff 2026)	None. Investigational; FDA filing planned for early 2027	Online vials sold with charts copied from trial protocols; we do not reproduce them	No. Not approved anywhere, so no pharmacy may compound it; vendors were warned in March and August 2026	Retatrutide

Growth hormone secretagogues

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
Sermorelin	1 mg subcutaneously twice daily for 14 days in 10 healthy men, mean age 68: GH and IGF-1 restored to young-adult levels; 0.5 mg did not work (Corpas 1992). 2 mg nightly for 6 weeks in 11 men aged 64 to 76: overnight GH up, IGF-1 unchanged, small strength gains (Vittone 1997)	None current. The pediatric product (Geref) was withdrawn in 2008 for commercial reasons	200 to 500 mcg nightly, 5 to 7 nights a week, from 3, 6 or 9 mg vials: three to seven times below the studied doses	Yes. Component of a formerly approved drug; never placed in Category 2	Sermorelin; dosage chart
Tesamorelin	2 mg subcutaneously once daily for 26 weeks; 412 adults with HIV and abdominal fat accumulation: visceral fat -15.2% versus +5.0% on placebo, IGF-1 up 81% (Falutz 2007)	Original Egrifta (the trial formulation): 2 mg once daily. Egrifta SV: 1.4 mg once daily (0.35 mL of a 2 mg vial mixed with 0.5 mL). Egrifta WR: 1.28 mg once daily, drawn as 0.16 mL from an 11.6 mg vial reconstituted with 1.3 mL (8 mg per mL) (Egrifta WR label)	1 to 2 mg nightly, 5 to 7 nights a week, in products clinics sell as compounded: inside the studied range, but without the daily dosing and the CT scans of the trials	No. A biological product, which cannot be compounded under 503A or 503B; brand Egrifta only, and off-label use of the brand is the prescriber's decision	Tesamorelin
CJC-1295 (with DAC)	Single subcutaneous doses, with 30 and 60 mcg/kg (about 2 to 4 mg for a 70 kg adult) best tolerated, then two or three doses weekly or every two weeks for up to 49 days; healthy adults aged 21 to 61: GH up 2- to 10-fold for 6 days or more, IGF-1 up 1.5- to 3-fold for 9 to 11 days (Teichman 2006). The no-DAC version has no published human study	None. Never approved	100 to 300 mcg of the no-DAC version nightly with ipamorelin, or 1 to 2 mg of the DAC version once or twice a week (seller charts)	No. Category 2 from September 2023, now listed by FDA as nominated but withdrawn; FDA's advisory committee voted 13 to 0 against it in December 2024	CJC-1295 and ipamorelin
Ipamorelin	0.03 mg/kg (about 2 mg) intravenously twice daily for up to 7 days after bowel surgery; 117 adults: no difference from placebo on recovery; well tolerated (Beck 2014). No subcutaneous dose has been studied	None. Never approved	100 to 300 mcg subcutaneously nightly, often 5 nights a week (seller charts)	No. Category 2 from September 2023, now listed by FDA as nominated but withdrawn; the committee voted 12 to 0 against it, with one abstention, in October 2024	CJC-1295 and ipamorelin

Healing and inflammation peptides

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
BPC-157	Humans: three uncontrolled pilot studies from one clinic, about 30 people in total. 10 mg injected around the bladder wall once during cystoscopy in 12 women with interstitial cystitis (Lee 2024); 10 and 20 mg intravenous infusions in 2 people. Rats: 10 mcg/kg into the abdomen daily, with the same healing reported at 10 ng/kg and 10 pg/kg (Staresinic 2003)	None. Never approved anywhere	250 to 500 mcg subcutaneously once or twice daily for 4 to 12 weeks; 500 mcg capsules (seller charts, apparently scaled from the rat dose)	No. Off Category 2 since April 15, 2026; recommended 8-6-1 by the advisory committee on July 23, 2026 against FDA reviewers' advice; no rule published (FDA Law Blog 2026)	BPC-157
TB-500 (thymosin beta-4 fragment)	No human study of the fragment; FDA said at the July 2026 meeting that there are no studies on TB-500 itself (FDA Law Blog 2026). The human trials cited for it used full-length thymosin beta-4 as eye drops, skin gel or intravenous infusion; the one rat study of the fragment (2026) used 60 mcg/kg daily	None. Never approved	2 to 2.5 mg subcutaneously twice a week for 4 to 6 weeks, then 2 to 5 mg once or twice a month (seller charts, traceable to no study)	No. Same position as BPC-157: off Category 2, recommended 8-6-1 in July 2026, no rule	TB-500
KPV	No human study and no registered trial; FDA's reviewers opposed listing in July 2026 for want of human data (FDA Law Blog 2026). Mice only: KPV in drinking water or in colon-targeted nanoparticles reduced chemically induced colitis	None. Never approved	250 to 500 mcg capsules once or twice daily, 200 to 500 mcg subcutaneously, nasal sprays (seller charts)	No. Recommended 8-6-1 on July 23, 2026 for wound healing and inflammatory conditions; no rule	KPV; KPV dosage chart

Sexual function

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
PT-141 (bremelanotide)	Women: 1.75 mg subcutaneously as needed, at least 45 minutes before sex; 1,247 premenopausal women with hypoactive sexual desire disorder, 24 weeks: desire and distress scores about 0.3 points better than placebo (Vyleesi label). Men: 0.3 to 10 mg subcutaneously in healthy men, with significant erections above 1 mg, and 4 and 6 mg in men with an inadequate response to sildenafil (Rosen 2004); intranasal doses of 7.5 to 20 mg in the 2004 to 2006 studies	Vyleesi: 1.75 mg subcutaneously as needed; no more than one dose in 24 hours and no more than 8 doses a month; stop after 8 weeks without improvement (Vyleesi label)	1 to 2 mg subcutaneously from a 10 mg vial; nasal sprays labeled around 1 to 2 mg per spray: below the doses that worked in men and, at 1 mg, below the only dose shown to work in women	Yes. Component of an approved drug, subject to the rule against routinely compounding what is essentially a copy of Vyleesi	PT-141

Skin

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
GHK-Cu (copper peptide)	Topical only: creams, gels and serums at about 0.1 to 2 percent, once or twice daily for 2 to 12 weeks, in small cosmetic and wound studies, including one 18-person eyebrow study in 2026 and one negative 13-person post-laser study (Mateescu 2026). Injectable: no human study of any kind	None. Topical products are cosmetics (copper tripeptide-1)	1 to 2 mg subcutaneously daily, five days a week, or 2 to 5 mg two or three times a week, from 50 mg vials (seller charts); about 2.5 mg per injection inside GLOW or KLOW blends	Injectable: no. Off Category 2 since April 2026; advisory review due by February 2027. Topical: legal as a cosmetic sold without drug claims, and compoundable on prescription under FDA's interim Category 1 policy since May 2026	GHK-Cu; GLOW and KLOW

Metabolic and mitochondrial

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
MOTS-c	Mice only: 5 mg/kg a day into the abdomen for 7 days improved glucose clearance and muscle insulin sensitivity; 0.5 mg/kg a day for 8 weeks prevented diet-induced obesity (Lee 2015). No human has received MOTS-c in a trial; a modified analog (CB4211) was given at 25 mg daily for 4 weeks to 20 adults and then dropped	None. Never approved	5 to 10 mg subcutaneously two or three times a week, in 4- to 8-week cycles (seller charts)	No. Recommended 7-5-2 on July 23, 2026 against FDA reviewers' advice; no rule	MOTS-c
AOD-9604	Oral tablets only: 1 to 30 mg daily for 12 weeks in 300 obese adults, then 0.25 to 1 mg daily for 24 weeks in about 530 obese adults; the 24-week trial showed no significant weight loss and development ended in 2007 (Valentino 2010). No injection has ever been tested for fat loss	None. Never approved	250 to 500 mcg subcutaneously once daily; 500 mcg to 1 mg under the tongue (seller charts)	No. Category 2 from September 2023, now listed by FDA as nominated but withdrawn; FDA proposed not to add it after the December 2024 review	AOD-9604

Sleep

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
DSIP (emideltide)	30 nmol/kg (about 1.8 mg for a 70 kg adult) by slow intravenous injection, six doses over one week; 18 chronic insomniacs aged 29 to 83, no placebo group described (Schneider-Helmert 1986). Two independent double-blind studies at 25 nmol/kg found no meaningful benefit, and nothing on sleep has been published since 1992	None. Never approved	100 to 300 mcg subcutaneously 30 to 60 minutes before bed, several nights a week; nasal sprays (seller charts, by a route never studied in humans)	No. Off Category 2 since April 2026; the advisory committee voted 6 to 7 against it on July 24, 2026	DSIP

Cofactors sold alongside peptides

Compound	What was studied (dose, route, frequency, population, duration)	Label dose	What clinics or sellers typically use (practice or claims, not recommendations)	May a US pharmacy compound it? (October 2026)	Hub
NAD+ (a coenzyme, not a peptide)	Intravenous: 750 mg over 6 hours (3 micromoles a minute) in a pharmacokinetic pilot of 8 adults: cleared from plasma for the first 2 hours, with a metabolite pattern of breakdown outside cells (Grant 2019). No published trial of subcutaneous or intramuscular NAD+. Oral precursors (NR, NMN) have dozens of small trials and one negative phase 3	None. No approved NAD+ drug	50 to 100 mg subcutaneously or intramuscularly one to three times a week, some programs 500 mg or more weekly; 250 to 1,000 mg intravenously over 1 to 4 hours (clinic listings)	Yes, under FDA's interim policy: NAD and NADH sit in Category 1 while FDA's 2019 proposal not to add them remains unfinished	NAD+
Glutathione (a tripeptide)	Oral: 500 mg a day in two doses for 4 weeks in 60 healthy adults: melanin index lower at 2 of 6 sites versus placebo (Arjinpathana 2012). Intravenous: 1,400 mg three times a week for 4 weeks in 21 adults with Parkinson's disease: no difference from placebo (Hauser 2009). No trial of intravenous or intramuscular glutathione for skin, detox, energy or immunity	None. No approved glutathione drug	600 to 1,200 mg intravenously one to three times a week; 200 to 600 mg intramuscularly once or twice a week; 200 mg per mL multi-dose vials for home use	Yes. Category 1 (interim policy). FDA warned compounders in 2019 and on August 27, 2026 against supplement-grade powder after endotoxin illnesses	Glutathione injections

Reconstitution and units: the arithmetic behind every row

A dose in the chart becomes a volume in a syringe through three numbers: how much peptide the vial holds, how much liquid it is dissolved in, and the dose. The formulas are the same for every compound.

Concentration (mcg per mL) = vial mg times 1,000, divided by water mL.
Volume per dose (mL) = dose in mcg divided by concentration.
Units on a U-100 insulin syringe = volume in mL times 100.

For a vial that arrives already in solution, the label gives the concentration directly, and the whole calculation collapses to one line: units = dose in mg divided by concentration in mg per mL, times 100. The peptide calculator runs both versions, and how many units are in 1 mL explains the syringe scale if it is new to you.

Example concentrations

The doses in this table are arithmetic examples drawn from the chart above, chosen to show how the same formula behaves across compounds. They are not recommendations.

Vial and diluent	Concentration	Example dose	Volume	Units
Sermorelin 6 mg plus 3 mL bacteriostatic water	2,000 mcg per mL	300 mcg	0.15 mL	15
Sermorelin 6 mg plus 1 mL	6,000 mcg per mL	300 mcg	0.05 mL	5 (hard to read accurately)
Bremelanotide 10 mg plus 2 mL	5,000 mcg per mL	1.75 mg (the Vyleesi dose)	0.35 mL	35
Tesamorelin, Egrifta WR 11.6 mg plus 1.3 mL	8 mg per mL	1.28 mg (label dose)	0.16 mL	16
Semaglutide solution, 2.5 mg per mL	2.5 mg per mL	0.25 mg (first label step)	0.1 mL	10
Semaglutide solution, 5 mg per mL	5 mg per mL	0.25 mg	0.05 mL	5
Tirzepatide solution, 10 mg per mL	10 mg per mL	5 mg	0.5 mL	50
NAD+ solution, 200 mg per mL	200 mg per mL	100 mg	0.5 mL	50
Glutathione solution, 200 mg per mL	200 mg per mL	400 mg	2 mL	200, which is two full syringes and why clinics split it or use an intravenous line

Three points follow. More water means more units per dose, a feature for small doses: 5 units is barely a mark and a half on a 100-unit syringe, 15 units is easy to read. The same number of units means different amounts of drug from vials of different concentration, which is why the concentration belongs on the vial in your handwriting the moment you mix it. And a dose that will not fit in one syringe is a sign the product, route or dose is wrong for home injection, not a reason to inject twice.

The technique, the diluent question and the 28-day rule for an opened multi-dose vial are in how to reconstitute peptides; refrigeration, beyond-use dates and travel are in how to store peptides; and the reasons two vials should not meet in one syringe are in the mixing compatibility chart.

Why the 'protocols' circulating online are not doses

Search for almost any compound in the chart and you will find a confident schedule: so many micrograms, so many days a week, a loading phase, a cycle. Those schedules look like the label tables above and are not the same kind of object, for five reasons.

They have no origin. A label dose is the end of a process: dose-ranging studies, a pivotal trial, a review of the data. A trial dose is at least a number someone chose, tested and published with the result. The seller numbers can rarely be traced to anything: the TB-500 schedule appears to have been copied from forum to forum since the horse-racing days, the 200 mcg of each for CJC-1295 and ipamorelin spread from forum to clinic menu, and the KPV chart looks like the BPC-157 chart with the name changed.

Where they do have an origin, it is a rodent, and the scaling is guesswork. BPC-157 at 10 mcg/kg in a rat becomes 700 mcg a day for a 70 kg adult by body weight, or about 110 mcg by body surface area, the method FDA's guidance uses; the seller range of 250 to 500 mcg sits between the two and is supported by neither. MOTS-c at 0.5 mg/kg a day in a mouse corresponds to roughly 3 mg a day in a person by surface area, and at 5 mg/kg to roughly 28 mg; the vendor charts of 10 to 30 mg a week by a different route match no study by any scaling. TB-500 at 60 mcg/kg a day in rats would be about 4 mg a day by weight or under 1 mg by surface area, not 2.5 mg twice a week. A conversion is a starting guess for a first-in-human study nobody has run.

The route is often the wrong one. DSIP was studied as a slow intravenous injection of about 1.8 mg; the charts sell 100 to 300 mcg under the skin. Ipamorelin's only efficacy trial was intravenous, twice daily, at about 2 mg; the charts sell a fraction of that subcutaneously. AOD-9604 was tested as tablets and is sold as injections and drops; GHK-Cu was studied as a cream and is sold as a vial. A dose established by one route says nothing about another.

The gap cuts both ways. Sermorelin is the clearest case of underdosing: 200 to 500 mcg nightly against the 1 to 2 mg a day that moved growth hormone and IGF-1 in the trials, with no study showing the lower dose does anything. Glutathione is the opposite: clinics infuse 600 to 1,200 mg one to three times a week, at or above the dose that failed against placebo in the one randomized intravenous trial, while the oral doses behind the modest documented effect cost less than a single session. Men prescribed 1 to 2 mg of PT-141 are below the 4 mg that produced erections in 2004; women prescribed 1 mg are below the only dose shown to work. The honest question is always the same: what is the evidence that this dose, by this route, does the thing it is being sold for?

The product has no label to apply the number to. For semaglutide, tirzepatide, tesamorelin, sermorelin, bremelanotide, glutathione and NAD+, a prescription produces a vial with a named pharmacy, a concentration and a beyond-use date, and the arithmetic above means something. For BPC-157, TB-500, KPV, MOTS-c, CJC-1295, ipamorelin, AOD-9604, DSIP, retatrutide and injectable GHK-Cu there is no such vial in the United States in October 2026; the chart assigns a dose to a research vial whose content nobody has verified, and FDA's 2026 warning letters treated the dosing guides and reconstitution calculators on vendor websites as evidence that the vials were drugs for people.

What a dose needs, then, is not a number but a chain: a labeled product with a known concentration, a prescriber who chose the dose for a reason, a route and frequency that were studied, and an outcome somebody measures, whether that is weight, IGF-1, visceral fat on a scan or a validated symptom score. A protocol supplies the number and skips the chain.

Using the chart with a prescription

If you are holding a prescription, four questions turn the chart into something useful.

Which column does my dose sit in? Tesamorelin at 1 to 2 mg nightly sits inside the studied range; sermorelin at 300 mcg sits well below it; a glutathione drip at 1,200 mg sits above the dose that failed. None of that settles whether the prescription is right for you, but each is worth a question to the prescriber.
Do my units match the concentration on the label? Run the vial through the calculator and compare; if they disagree, call the pharmacy before injecting.
Which pharmacy made it, and on what basis? If the compoundable column says no, a licensed pharmacy did not fill the prescription, whatever the paperwork says.
What will be measured, and when? A studied dose came with an outcome. A prescription should too.

Bottom line

The compounds with real dosing information are the ones with labels and trials: the GLP-1 drugs, tesamorelin, bremelanotide and, with 1990s data, sermorelin, plus the oral and intravenous studies of glutathione and NAD+ that mostly show how little the injectable routes have been tested. For most of the rest, the honest entry in a dosage chart is 'no human dose has been studied', and the figures on seller charts are claims about a product no US pharmacy may make. Read the numbers here the way they were generated, as the doses that produced a measured result in a described group of people, and let the pharmacy label decide what goes in the syringe.

Frequently asked questions

+Is there a peptide dosage chart I can follow?

Not in the sense of a chart that tells you what to inject. The chart on this page lists what published studies and FDA labels used, with the population and duration, next to what clinics and sellers typically use, so you can see where a prescription or a vendor chart sits against the evidence. For an approved drug such as semaglutide, tirzepatide, tesamorelin or bremelanotide, the label is the dosing authority. For a compounded prescription, the dose on your pharmacy label is. For research vials there is no label, and no chart from a website changes that.

+How much peptide should you inject?

Whatever your pharmacy label says, measured as a volume from the concentration printed on it. There is no general answer, because the studied doses range from micrograms (sermorelin, bremelanotide) to milligrams (tesamorelin, the GLP-1 drugs, glutathione), and the route and frequency differ for each compound. The arithmetic is the same for all of them: units on a U-100 insulin syringe equal the dose in mg divided by the concentration in mg per mL, times 100.

+How many units is 1 mg of a peptide?

It depends entirely on the concentration of the vial. Units measure volume, not peptide: 100 units equal 1 mL on every standard insulin syringe. A 1 mg dose is 100 units from a 1 mg per mL vial, 50 units from a 2 mg per mL vial and 20 units from a 5 mg per mL vial. Reading a dose in units without knowing the concentration is how the 5- to 20-fold GLP-1 overdoses that FDA described in 2024 happened.

+What is a peptide protocol, and is it the same as a dose?

No. A dose is an amount of a labeled product, given by a stated route and frequency, that was tested in a population for a duration. A protocol, as the word is used online, is a schedule somebody wrote for an unlabeled vial, usually copied from a forum or a seller and often scaled by guesswork from a rodent study. Most circulating protocols concern compounds no US pharmacy may compound, so there is no labeled product to apply them to. This site reports studied doses and does not publish protocols.

+What is the sermorelin dosage chart?

The adult trials used 1 mg under the skin twice daily for 14 days (0.5 mg did nothing) and 2 mg nightly for 6 weeks; telehealth prescriptions are typically 200 to 500 mcg nightly, three to seven times lower. A common compounded vial is 6 mg reconstituted with 3 mL of bacteriostatic water, which gives 2,000 mcg per mL, so a 300 mcg dose is 0.15 mL, or 15 units. The sermorelin dosage chart page has the full table and the injection sites.

+Is there a MOTS-c dosage chart?

Not from any human study, because no human has received MOTS-c in a trial. The published doses are mouse doses: 0.5 and 5 mg per kilogram a day injected into the abdomen. The 5 to 10 mg two or three times a week on seller charts was written by sellers, and no US pharmacy may compound MOTS-c as of October 2026, so there is no labeled product to dose. Our MOTS-c profile lays the mouse doses next to the charts.

+What is the GLOW peptide dosage chart?

A seller's arithmetic for a vial that usually contains about 50 mg of GHK-Cu, 10 mg of BPC-157 and 10 mg of TB-500 freeze-dried together: reconstitute with 2 or 3 mL and inject 10 to 20 units a day. None of the three components has a studied injectable dose in humans, no study of the blend exists, and none of them may be compounded for injection by a US pharmacy. The GLOW and KLOW page takes the charts apart component by component.

+How much peptide should you take for weight loss?

The only peptides with studied weight-loss doses are the GLP-1 drugs: semaglutide stepped up over 16 weeks to 2.4 mg once weekly, and tirzepatide stepped up from 2.5 mg to 5, 10 or 15 mg once weekly. Those schedules produced about 15 percent and up to about 21 percent weight loss in the pivotal trials. Nothing else on this chart has a weight-loss dose established in people: AOD-9604 failed its trial, MOTS-c has mouse data only, and tesamorelin reduces visceral fat without changing weight.

+What is the PT-141 dosage chart for women and men?

For women, the only labeled dose is 1.75 mg under the skin as needed, at least 45 minutes before sex, no more than one dose in 24 hours and no more than eight a month. Men have no labeled dose; the 2004 phase 2 studies used 0.3 to 10 mg under the skin in healthy men, with effects above 1 mg, and 4 and 6 mg in men who responded poorly to sildenafil. Compounded prescriptions are commonly 1 to 2 mg, below the doses that worked in men.

+How much bacteriostatic water do I add to a peptide vial?

The volume on your pharmacy label. The water does not change how much peptide is in the vial, only the concentration and therefore the units per dose: 5 mg in 1 mL is 5,000 mcg per mL, in 2 mL it is 2,500 mcg per mL, in 2.5 mL it is 2,000 mcg per mL. More water means more units per dose, which makes small doses easier to measure. The reconstitution guide and the calculator do the arithmetic for any vial.